Infinity and MedImmune Announce Promising Biological Activity of Anti-Hsp90 Compound in Phase I GIST Trial
09-Nov-2006 -
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. announced preliminary results from an open-label Phase I clinical study of IPI-504 in patients with Gleevec®-resistant metastatic gastrointestinal stromal tumors (GIST). IPI-504, Infinity's lead oncology drug candidate, is a proprietary small ...
gastrointestinal stromal tumor
inhibitors
MedImmune
+2